Every 10-Q that Kopin Corp (KOPN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KOPN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KOPN filings page.
Kopin Corporation reported improved results for the three and six months ended June 27, 2026. Total revenues were $12.7 million for the quarter and $23.3 million year‑to‑date, up from $8.5 million and $19.0 million in the prior‑year periods, driven by higher defense, grant and collaboration revenues. The company generated quarterly net income of $0.8 million versus a $5.2 million loss a year earlier, with a six‑month net loss narrowing to $2.9 million from $8.3 million, aided by a $4.6 million gain on investments and a $2.1 million tax benefit.
Cash and cash equivalents were $24.9 million, plus $25.4 million of restricted cash largely tied to a supersedeas bond securing a $19.7 million litigation judgment. Operating activities used $5.1 million of cash in the first half, reflecting ongoing R&D investment. The company entered a Joint Development & License Agreement with Fabric.AI, under which $15 million of development funding has been received and $5.2 million remains in contract liabilities. Remaining performance obligations under customer contracts totaled $49.1 million, with $40.3 million expected to be recognized as revenue over the next 12 months.
Kopin Corporation reported first‑quarter 2026 revenues of $10.6 million, essentially flat year over year, and a net loss of $3.8 million, or $0.02 per share. Net product revenues fell to $5.4 million, mainly from lower defense display volumes, but were offset by $3.4 million of grant income and $0.3 million of collaboration income.
Product gross margin turned slightly negative as cost of product revenues exceeded product sales, which management attributes to reduced production efficiency and lower volume. Operating expenses rose, driven by higher funded R&D tied to a U.S. government MicroLED grant and increased selling, general and administrative costs.
Non‑operating income improved to $2.3 million, largely from gains on investments, partially cushioning the operating loss. Kopin ended the quarter with $34.1 million in cash and cash equivalents and $25.3 million in restricted cash, including funds securing a $23.0 million supersedeas bond related to the BlueRadios judgment. Management believes current cash supports operations and obligations for at least the next twelve months and highlights ongoing strategic partnerships with Theon and a new joint development and supply agreement with Fabric.AI.
Kopin Corporation reported Q3 2025 results. Total revenue was $11.96 million versus $13.32 million a year ago, as lower research and development revenue offset steady defense-driven product sales. Operating income reached $4.53 million compared with a loss last year, primarily reflecting a $5.1 million litigation accrual reduction. Net income was $4.08 million (diluted EPS $0.02).
Year-to-date, revenue was $30.96 million versus $35.69 million and net loss narrowed to $4.20 million. Cash and cash equivalents were $26.51 million. The company ended the quarter with an accrued litigation liability of $19.7 million.
After quarter-end, Kopin posted a $23.0 million supersedeas bond related to the BlueRadios judgment, secured by a $24.2 million deposit classified as restricted cash. Remaining performance obligations totaled $39.1 million expected over the next 12 months. Shares outstanding were 182,513,346 as of November 12, 2025.
Kopin Corporation reported consolidated results for the three and six months ended June 28, 2025 showing continued revenue generation but ongoing losses and liquidity pressure. For the six months the company recorded $18.99 million of total revenue and a $8.28 million net loss; revenue declined versus the prior year period. Cash and cash equivalents were $24.37 million with $1.05 million of restricted cash, and combined cash, cash equivalents and restricted cash totaled $25.42 million at period end after significant sales of marketable securities.
Balance sheet and contingency items weigh on near-term prospects: marketable securities fell to $2.42 million from prior period levels, stockholders' equity was $16.04 million, and the company carries an accrued $24.8 million litigation damages amount. Management discloses substantial doubt about the company’s ability to continue as a going concern for twelve months and describes plans to reduce cash outflows and potentially raise capital. Defense end-market sales declined, while industrial and medical sales showed some increases; supply-chain risks for semiconductors remain a stated constraint.